

# **ONTARGET: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial**

**ACE-inhibitors (e.g. ramipril in the HOPE trial) reduces CV death, MI, stroke and HF hosp in those with CVD or DM in the absence of ventricular dysfunction or heart failure**

**ACE-inhibitors are not tolerated by 15% to 25% of patients**

**Will an ARB (telmisartan) be as effective and better tolerated?**

**Is the combination superior?**

# ONTARGET

## Questions:

1. Is telmisartan “non-inferior” to ramipril?
2. Is the combination superior to ramipril?

## Outcome:

1. Primary: CV death, MI, stroke, CHF hosp
2. Key secondary: CV death, MI, stroke (HOPE trial outcome)

## Design:

Single blind run-in (n=29,019)

Randomized, double blind, double dummy study conducted in 733 centers in 41 countries (n=25,620)

56 months follow-up with 99.8% outcome ascertainment

# ONTARGET **Statistical Considerations**

In HOPE the hazard ratio for ramipril v plac	:	0.77
40 <sup>th</sup> percentile	:	0.794
Excess risk of placebo/ramipril	:	1.26
Half of above	:	1.13

For non-inferiority (Telmisartan v ramipril) the one-sided 97.5% CI should be below 1.13.

Assuming an annual event rate of 3.97%, 7800 patients per group followed for 4.5 yrs provides :

- 89% power for NI (T v R)

- 93% power superiority (T + R v R)

Total randomized: 25,620 in 18 months

ONTARGET

# Study Medications Titration

## Run-in (Single Blind)

Day 1-3                      Ram 2.5 mg + Tel Placebo

Day 4-10                    Ram 2.5 mg + Tel 40 mg

Day 11-18                  Ram 5.0 mg + Tel 40 mg

## Randomization (Double Blind)

2 weeks                      Ram Placebo + Tel 80 mg

Ram 5 mg + Tel Placebo

Ram 5 mg + Tel 80 mg

Then                          Full doses (Tel 80 mg daily,

Ram 10 mg daily) for the 3 arms

ONTARGET

# Reasons for Not Randomizing Patients

		%
Run-in Completed (n=29,018)		100
Not Randomized		11.71
Creatinine elevated	0.22	
Potassium elevated	0.77	
Persistent symptomatic hypotension	1.70	
Death	0.09	
Total Medical Reasons		2.78
Compliance <75%	3.87	
Other reasons	3.01	
Patient Decision	2.06	
Total Patient Reasons		5.93

# ONTARGET **Key Baseline Characteristics**

	Ramipril	Telmisartan	Combination
N	8576	8542	8502
Age	66.4	66.4	66.5
% females	27.2	26.3	26.5
% CAD	74.4	74.5	74.7
% Stroke/TIA	21.0	20.6	20.9
% Diabetes	36.7	38.0	37.9
BP	141.8/82.1	141.7/82.1	141.9/82.1
Statins	61.0	62.0	61.8
Antiplatelet	80.5	81.1	81.1
$\beta$ -blocker	56.5	56.9	57.4


ONTARGET

## Change in BP (mmHg)

	Ramipril	Telmisartan	Combination
Systolic	-6.0	-6.9	-8.4
Diastolic	-4.6	-5.2	-6.0

# Time to Permanent Discontinuation of Study Medication

ONTARGET




ONTARGET

# Reasons for Permanently Stopping Study Medications

	Ram N=8576	Tel N=8542	Tel vs. Ram	
			RR	P
Hypotension	149	229	1.54	0.0001
Syncope	15	19	1.27	0.4850
Cough	360	93	0.26	<0.0001
Diarrhea	12	19	1.59	0.20
Angioedema	25	10	0.40	0.0115
Renal Impairment	60	68	1.14	0.46
Any Discontinuation	2099	1962	0.94	0.02

# ONTARGET **Time to Primary Outcome**

	# at Risk	Yr 1	Yr 2	Yr 3	Yr 4
T	8542	8176	7778	7420	7051
R	8576	8214	7832	7473	7095



ONTARGET

# Primary Outcome & HOPE


## Primary Outcome

	Ram	Tel	Tel vs Ram	
	N (%)	N (%)	RR (95% CI)	P (non-inf)
N	8576	8542		
<u>Primary Outcome</u>				
CV Death, MI, Stroke, CHF Hosp	1412 (16.46%)	1423 (16.66%)	1.01 (0.94-1.09)	0.0038
(Adjusted for SBP)			1.02 (0.95-1.10)	0.0055
<u>HOPE Primary Outcome</u>				
CV Death, MI, Stroke	1210 (14.11%)	1190 (13.93%)	0.99 (0.91-1.07)	0.0009
(Adjusted for SBP)			0.99 (0.91-1.07)	0.0012

# ONTARGET Non-Inferiority Comparison

ONTARGET

## Comparison




# ONTARGET Time to Primary Outcome

# at Risk Yr 1 Yr 2 Yr 3 Yr 4

R 8576 8214 7832 7473 7095

T&R 8502 8134 7740 7377 7023



ONTARGET

# Reasons for Permanently Stopping Study Medications

	Ram N=8576	Ram + Tel N=8502	Ram + Tel vs. Ram RR	P
Hypotension	149	406	2.75	<0.0001
Syncope	15	29	1.95	0.032
Cough	360	392	1.10	0.1885
Diarrhea	12	39	3.28	0.0001
Angioedema	25	18	0.73	0.30
Renal Impairment	60	94	1.58	0.0050
Any Discontinuation	2099	2495	1.20	<0.0001

**ONTARGET**

---

# **Combination vs Ramipril**

# Conclusions: Telmisartan vs. Ramipril (1)

1. Telmisartan is clearly “non-inferior” to ramipril
  - Primary composite outcome (p=0.0038)
  - HOPE primary outcome (p=0.001)

Most (>90%) of the benefits of ramipril are preserved
2. Consistent results on a range of:
  - Secondary outcomes
  - Subgroups

# Conclusions: Telmisartan vs. Ramipril (2)

3. Sensitivity analysis using a per protocol approach confirms this
4. Telmisartan exhibits slightly superior tolerability
  - Less cough and angioneurotic edema
  - More mild hypotensive symptoms, but no difference in severe hypotensive symptoms, such as syncope

# Conclusions: Telmisartan plus Ramipril vs. Ramipril

1. Combination therapy does not reduce the primary outcome to a greater extent compared to ramipril alone
2. Higher rates of adverse events:
  - hypotension related, including syncope
  - renal dysfunction

# Implications

- Telmisartan is as effective as ramipril, with a slightly better tolerability.
- Combination therapy is not superior to ramipril, and has increased side effects.